Pharmacokinetics of carboplatin in a patient with cervical cancer with ureteric obstruction before, during, and after hemodialysis.
The pharmacokinetics of total and free (ultrafilterable) platinum were investigated in a patient with cervical cancer with ureteric obstruction who, at the time of carboplatin administration, appeared to have a mild renal impairment (i.e., creatinine clearance 1 mL/s), but developed an acute renal failure shortly thereafter, which required hemodialysis. The decline in the concentration of total or free Pt in plasma as function of time correlated well (P < 0.0098) with that of serum creatinine concentration. The elimination half-lives (t1/2) of total and free Pt in this patient were eight- and nine-fold longer than those observed earlier for patients with normal renal function, and the total body clearance was 12.4% and 18.4%, respectively. Although t1/2 of Pt during dialysis was two to three times (total Pt) and eight times (free Pt) shorter than those observed before and after dialysis, three sessions of hemodialysis removed only 5.6% of total Pt and 9.3% of free Pt. Because the pre- and post-dialysis t1/2 values were similar, hemodialysis apparently had no impact on the intrinsic elimination of Pt in this patient.
el-Yazigi
A
A
Department of Biological and Medical Research, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Alfurayh
O
O
Amer
M
M
D058186:Acute Kidney Injury / Q000150:complications / Q000378:metabolism / Q000628:therapy; D000328:Adult; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D016190:Carboplatin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D008657:Metabolic Clearance Rate; D006435:Renal Dialysis; D013997:Time Factors; D014517:Ureteral Obstruction / Q000209:etiology / Q000378:metabolism*; D002583:Uterine Cervical Neoplasms / Q000150:complications / Q000378:metabolism*
D000970:Antineoplastic Agents; D016190:Carboplatin